- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05471726
퇴원 후 항균제 사용 개선
퇴원 후 항균제 사용 개선: 다기관 계단식 웨지 시험 연구
One in five hospitalized patients is prescribed an antimicrobial at the time of discharge, and a large proportion of these post-discharge antimicrobials are unnecessary. The investigators will evaluate a novel method for reviewing post-discharge antimicrobial prescriptions in real-time with the goal of improving antimicrobial selection and duration.
연구 개요
상세 설명
Antimicrobial stewardship programs (ASPs) work to improve antibiotic prescribing within hospitals. ASPs often restrict their activities to inpatient antimicrobial-prescribing. However, at least 40% of all antimicrobial exposure associated with an acute-care hospital stay is prescribed at the time of hospital discharge (i.e., post-discharge). Post-discharge antimicrobials mediate clinical outcomes after discharge and may facilitate the spread of antimicrobial resistance.
Several studies have shown that post-discharge antimicrobial use is often inappropriate. For example, using national VA data, the investigators found that 61% of fluoroquinolone treatment days were prescribed at hospital discharge; manual chart reviews at 9 hospitals found that 40% of these post-discharge fluoroquinolone prescriptions were either unnecessary or sub-optimal. Other studies have found that 53-79% of all post-discharge antimicrobials are either unnecessary or sub-optimal.
Post-discharge antimicrobials are an important target for antimicrobial stewardship. However, inpatient stewardship metrics do not capture post-discharge antimicrobials and ASPs frequently do not evaluate these prescriptions. A 2016 VA survey found that less than 50% of hospitals routinely reviewed targeted antimicrobials at discharge. According to a 2016 survey in Michigan, only 17% of 48 hospitals had a process for reviewing outpatient antimicrobial orders at discharge.
It is unclear how inpatient stewardship resources can be effectively leveraged to improve post-discharge antimicrobial use. If the goal is to improve post-discharge antimicrobial use, a potentially effective strategy may be an audit-and-feedback process focused solely on prescriptions for patients who will soon be discharged. In this trial, the investigators will evaluate the feasibility and effectiveness of such a process.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46202
- Richard Roudebush VA Medical Center
-
-
Iowa
-
Iowa City, Iowa, 미국, 52242
- University of Iowa Hospitals and Clinics
-
-
Maryland
-
Baltimore, Maryland, 미국, 21201-1524
- Baltimore VA Medical Center
-
-
Missouri
-
St Louis, Missouri, 미국, 63110
- Barnes Jewish Hospital and affiliated hospitals
-
-
Texas
-
San Antonio, Texas, 미국, 78229
- Audie L Murphy VA Medical Center
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
--The local stewardship team agrees to implement the discharge stewardship intervention on at least one inpatient service or ward.
Exclusion Criteria:
--The hospital already has an audit-and-feedback process in place that focuses on antimicrobial prescribing at hospital discharge.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 건강 서비스 연구
- 할당: 무작위
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Prospective audit-and-feedback at discharge
When hospitals are in the intervention arm, they will perform the audit-and-feedback process focused on patients receiving antimicrobials who have an anticipated discharge. |
The stewardship team will review patients who are on antibiotics, have an uncomplicated infection, and are eligible to continue antibiotics after discharge. Any recommendations from the stewardship team about optimizing antibiotic therapy will be presented to the primary prescriber in real-time with the goal of improving antibiotic selection and duration at hospital discharge. |
|
간섭 없음: Standard of care
When hospitals are in the control arm, they will not perform a stewardship process that focuses on hospital discharge. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Patients With Post-discharge Antibiotic Exposure
기간: Antibiotics prescribed at the time of hospital discharge for the patient to take after discharge
|
Post-discharge antibiotic exposure captures the number of hospitalized patient who were discharged with an antibiotic to take after discharge. |
Antibiotics prescribed at the time of hospital discharge for the patient to take after discharge
|
|
Length of Post-discharge Antibiotic Therapy
기간: Antibiotics prescribed at the point of hospital discharge
|
Duration in days of the post-discharge antibiotics that were prescribed |
Antibiotics prescribed at the point of hospital discharge
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Inpatient Antibiotic Length of Therapy
기간: Every two-week period through study completion (48 weeks total)
|
Inpatient antibiotic LOT will be calculated by measuring inpatient LOT across all patients exposed to inpatient antibiotics on the participating services during the study period. |
Every two-week period through study completion (48 weeks total)
|
|
Percentage of Participants With Hospital Readmission
기간: 30 days from discharge
|
Hospital readmissions reflect the need for (re) admission to an acute-care bed at a participating facility for any indication within 30 days of the patient's discharge. |
30 days from discharge
|
공동 작업자 및 조사자
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
All data will be aggregated to the hospital-level without including patient identifiers. This is a requirement for transmitting data across the institutions participating in this trial.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .